C1q modulation of antibody-dependent enhancement of dengue virus infection in human myeloid cell lines is dependent on cell type and antibody specificity
Microbes and Infection · 2024
DOI: 10.1016/j.micinf.2024.105378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbes and Infection, 2024. Verfasst von Alana B Byrne und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Investigaciones Infectológicas y Biología Molecular, Infectología, Departamento de Medicina, Hospital de Niños Dr. Ricardo Gutiérrez, …. Hauptthemen laut MEDLINE: Dengue Virus, Antibody-Dependent Enhancement, Complement C1q, Myeloid Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Consejo Nacional de Investigaciones Científicas y Técnicas, Agencia Nacional de Promoción de la Investigación el Desarrollo Tecnológico y la Innovación.
Abstract (Originalsprache)
Antibody-dependent enhancement (ADE) of dengue virus (DENV) infection is one of the mechanisms contributing to increased severity during heterotypic, secondary infection. The complement protein C1q has been shown to reduce the magnitude of ADE in vitro. Therefore, we investigated the mechanisms of C1q modulation of ADE, focusing on processes of viral entry. Using a model of ADE of DENV-1 infection in human myeloid cell lines in the presence of monoclonal antibodies, 4G2 and 2H2, we found that C1q produced nearly a 40-fold reduction of ADE of DENV-1 in K562 cells, but had no effect in U937 cells. In K562 cells, C1q reduced adsorption of DENV-1/4G2 and exerted a dual inhibitory effect on adsorption and internalization of DENV-1/2H2. Distinct endocytic pathways in the presence of antibody corresponded to conditions where C1q produced a differential action. Also, C1q did not affect the intrinsic cell response mediated by FcγR in human myeloid cells. The modulation of ADE of DENV-1 by C1q is dependent on the FcγR expressed on immune cells and the specificity of the antibody comprising the immune complex. Understanding protective and pathogenic mechanisms in the humoral response to DENV infections is crucial for the successful design of antivirals and vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Investigaciones Infectológicas y Biología Molecular, Infectología, Departamento de Medicina, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo 1330, Buenos Aires 1425, Argentina; Fundación INFANT, Gavilán 94…
- Laboratorio de Investigaciones Infectológicas y Biología Molecular, Infectología, Departamento de Medicina, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo 1330, Buenos Aires 1425, Argentina; Universidad de Buenos Aires,…
- Departamento de Medicina, Programa de Infectología Pediátrica, Hospital de Niños Dr. Ricardo Gutiérrez, Universidad de Buenos Aires, Gallo 1330, Buenos Aires 1425, Argentina.
- Fundación INFANT, Gavilán 94, Buenos Aires 1406, Argentina.
Förderung
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Agencia Nacional de Promoción de la Investigación el Desarrollo Tecnológico y la Innovación
Zitieren
APA
Byrne, A. B., Bonnin, F. A., López, E. L., Polack, F. P., & Talarico, L. B. (2024). C1q modulation of antibody-dependent enhancement of dengue virus infection in human myeloid cell lines is dependent on cell type and antibody specificity. Microbes and Infection. https://doi.org/10.1016/j.micinf.2024.105378
Vancouver
Byrne AB, Bonnin FA, López EL, Polack FP, Talarico LB. C1q modulation of antibody-dependent enhancement of dengue virus infection in human myeloid cell lines is dependent on cell type and antibody specificity. Microbes and Infection. 2024. doi:10.1016/j.micinf.2024.105378
BibTeX
@article{Byrne2024,
author = {Byrne, Alana B and Bonnin, Florencia A and López, Eduardo L and Polack, Fernando P and Talarico, Laura B},
title = {C1q modulation of antibody-dependent enhancement of dengue virus infection in human myeloid cell lines is dependent on cell type and antibody specificity},
journal = {Microbes and Infection},
year = {2024},
doi = {10.1016/j.micinf.2024.105378}
}
EUVIMED